

Dangi AA, Sheth NR, Sodha HH, Joshi PC, Bhalodiya DS, Panchal AC, Ramanuj PR. Formulation and development of vaccines and their selection for next generation. *Bull. Pharm. Res.* 2011;1(3):49-62.

References (28):

1. Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9 N2 vaccine preparations. *Clin. Infect. Dis.* 2006;43(9): 1135-42.
<http://cid.oxfordjournals.org/content/43/9/1135.full.pdf>
2. Bernstein D, Cardin R, Strasser J, Chalk C, Farley N, Fairman J. Juvimmune is a novel vaccine adjuvant that enhances protection of mice from lethal HSV-2 infection following immunization. In: Infectious Diseases Society of America 45th Annual Meeting, San Diego, CA; 2007: presentation 1147.
3. Brewer JM. (How) do aluminium adjuvants work? *Immun. Lett.* 2006;102(1):10-5.
<http://drtenpenny.com/Documents/How%20do%20aluminum%20adjuvants%20work.pdf>
4. Burdin N, Guy B, Moingeon P. Immunological foundations to the quest for new vaccine adjuvants. *BioDrugs* 2004;18(2):79-93.
<http://adisonline.com/biodrugs/pages/articleviewer.aspx?year=2004&issue=18020&article=00002&type=abstract>
5. dela Cruz T, Milley R, Hillebrand A. Conjugation of Immunostimulatory DNA to Conserved Viral Antigens as a Universal Influenza Vaccine. In: Infectious Diseases Society of America 45th Annual Meeting, San Diego, CA; 2007: presentation 1145.
6. Dellepiane N, Griffiths E, Milstien JB. New challenges in assuring vaccine quality. *Bull. World Health Organ.* 2000;78(2):155-62.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2560684/pdf/10743279.pdf>
7. Dowdle WR, De Gourville E, Kew OM, Pallansch MA, Wood DJ. Polio eradication: the OPV paradox. *Rev. Med. Virol.* 2003;13(5):277-91.
<http://onlinelibrary.wiley.com/doi/10.1002/rmv.401/abstract;jsessionid=D3F9A4601EA6852F23860A9FF5131627.d01t04>
8. Frech SA, Kenney RT, Spyr CA, Lazar H, Viret J-F, Herzog C, Gluck R, Glenn GM. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. *Vaccine* 2005;23(7):946-50.
<http://www.sciencedirect.com/science/article/pii/S0264410X04005249>

9. Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. *Expert Rev. Vaccines* 2007;6(5):723-39. http://www.expert-reviews.com/doi/abs/10.1586/14760584.6.5.723?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
10. Gotschlich EC, Rey M, Triaux R, Sparks KJ. Quantitative determination of the human immune response to immunization with meningococcal vaccines. *J. Clin. Invest.* 1972;51(1): 89-96. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC332933/pdf/jcinvest00636-0109.pdf>
11. Guy B. The perfect mix: recent progress in adjuvant research. *Nat. Rev. Microbiol.* 2007; 5(7):505-17. <http://www.nature.com/nrmicro/journal/v5/n7/full/nrmicro1681.html>
12. Janeway Jr. CA, Medzhitov R. Innate immune recognition. *Annu. Rev. Immunol.* 2002;20: 197-216. <http://www.cals.uidaho.edu/mmbb/kgustin/mmbb471571/Papers/JanewayandMedzhito v.pdf>
13. Lagos R, Valenzuela MT, Levine OS, Losonsky GA, Erazo A, Wasserman SS, Levine MM. Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. *Lancet* 1998;351(9114):1472-6. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(97\)07456-4/fulltext](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(97)07456-4/fulltext)
14. Lang J, Wood SC. Development of orphan vaccines: an industry perspective. *Emerg Infect. Dis.* 1999;5(6):749-56. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2640802/pdf/10603207.pdf>
15. Laurent PE, Bonnet S, Alchas P, Regolini P, Mikszta JA, Pettis R, Harvey NG. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. *Vaccine* 2007;25(52):8833-42. <http://www.sciencedirect.com/science/article/pii/S0264410X07011565>
16. Lindblad EB. Aluminium adjuvants--in retrospect and prospect. *Vaccine* 2004;22(27-28): 3658-68. <http://www.sciencedirect.com/science/article/pii/S0264410X04002750>
17. Luke CJ, Subbarao K. Vaccines for pandemic influenza. *Emerg. Infect. Dis.* 2006;12(1):66-72. <http://www.ncbi.nlm.nih.gov/pubmed/16494720>
18. Mbawuike I, Zang Y, Couch RB. Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant. *Vaccine* 2007; 25(17):3263-9. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2017113/pdf/nihms21999.pdf>
19. Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, Dunn J, DeStefano F, Shay D. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. *J. Infect. Dis.* 2006;194(8):1032-9. <http://jid.oxfordjournals.org/content/194/8/1032.full.pdf>

20. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/ Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. *Lancet* 2001; 357(9272):1937-43.
[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(00\)05066-2/fulltext](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)05066-2/fulltext)
21. O'Hagan DT, Rappuoli R. Novel approaches to vaccine delivery. *Pharm Res.* 2004;21(9): 1519-30.
<http://www.springerlink.com/content/p343t5mh02540483/>
22. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. *Nat. Med.* 2005;11(4):S63-8.
<http://www.nature.com/nm/journal/v11/n4s/full/nm1210.html>
23. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. *Immunol. Cell Biol.* 2004;82(5):488-96.
<http://www.nature.com/icb/journal/v82/n5/pdf/icb200475a.pdf>
24. Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. *Expert. Rev. Vaccines* 2003;2(2):197-203.
<http://www.ncbi.nlm.nih.gov/pubmed/12899571>
25. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: Implications for vaccine development. *Cell* 2006;124(4):849-63.
<http://www.ncbi.nlm.nih.gov/pubmed/16497593>
26. Stephenson I, Bugarini R, Nicholson KG, podda A, Wood JM, Zambon MC, Katz JM. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. *J. Infect. Dis.* 2005;191(8):1210-5.
<http://jid.oxfordjournals.org/content/191/8/1210.full.pdf>
27. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. *N. Engl. J. Med.* 2006;354(13):1343-51.
<http://www.nejm.org/doi/full/10.1056/NEJMoa055778#t=article>
28. Vogel FR, Hem SL. Immunologic Adjuvants. In: Plotkin SA, Orenstein WA, eds. *Vaccines.* 4th ed. Philadelphia, PA: Saunders; 2004: 69-79.